Herpes Virus Shows Promise in Treating Advanced Skin Cancer

Scientists have developed a genetically modified herpes simplex virus, RP1, which has shown promise in shrinking advanced melanoma tumors, including those deep inside the body, in a phase 1/2 clinical trial. The therapy, especially when combined with the immune drug nivolumab, has demonstrated significant tumor reduction in a substantial portion of patients, offering hope for more effective treatment options for melanoma, particularly in cases resistant to current therapies.